Invitrogen

Human CLEC2D (aa 60-160) Control Fragment Recombinant Protein

Name: Human CLEC2D (aa 60-160) Control Fragment Recombinant Protein
Brand: Invitrogen
SKU: RP-89969

Datasheet

Tech Support

Datasheet

Tech Support

Product Details

RP-89969

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

RANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGA

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

1M urea/PBS, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (47%), Rat (47%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-53617. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

Recently, Zhou et al have identified a protein that can inhibit multinucleate Osteoclast formation in murine osteoblast and spleen cell co-cultures. This protein called, Osteoclast Inhibitory Lectin (OCIL) can also inhibit osteoclast formation in spleen cell cultures treated with RANKL and M-CSF. Furthermore, mOCIL acted directly on macrophage/monocyte cells as evidenced by its inhibitory action on adherent spleen cell cultures, which were depleted of stromal and lymphocytic cells. mOCIL completely inhibited osteoclast formation during the proliferative phase of osteoclast formation and resulted in 70% inhibition during the differentiation phase. Osteoblast OCIL mRNA expression was enhanced by parathyroid hormone, calcitriol, interleukin-1 and IL-11, and retinoic acid. OCIL is expressed in osteoblasts and chondrocytes as well as in a variety of extraskeletal tissues. Since OCIL expression was found to be very similar to distribution for RANKL, it has been suggested that RANKl and OCIL may interact in skeleton and in extracellular tissues.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: C-type lectin domain family 2 member D; C-type lectin domain family 2, member D; C-type lectin related f; C-type lectin superfamily 2, member D; Lectin-like NK cell receptor; Lectin-like transcript 1; LLT-1; MGC123478; Osteoclast inhibitory lectin